GLP-1 Receptor Agonists and Ovarian Cancer: Evidence Review for Clinicians
# GLP-1 Receptor Agonists and Ovarian Cancer: Evidence Review for Clinicians
Executive Summary
A converging body of evidence from large observational cohorts, systematic reviews, and Mendelian randomization studies supports a protective association between GLP-1 receptor agonist (GLP-1 RA) use and ovarian cancer risk and outcomes. The evidence is strongest for risk reduction (approximately 43–47% lower incidence in GLP-1 RA users) and for a survival benefit (approximately 55% lower all-cause mortality in women with existing ovarian cancer). However, all human data are observational or genetic; no randomized trials with ovarian cancer as a primary endpoint have been completed.
---
Key Studies
1. Ovarian Cancer Incidence — GLP-1 RA Users vs. Non-Users
Primary study: Boateng et al., JAMA Oncology 2025 - Retrospective cohort, 86,632 adults with overweight/obesity (43,317 GLP-1 RA users vs. 43,315 propensity-matched non-users) - Overall cancer incidence: HR 0.83 (95% CI 0.76–0.91) - Ovarian cancer: HR 0.53 (95% CI 0.29–0.96) — approximately 47% relative risk reduction - Also reduced: endometrial cancer (HR 0.75), meningioma (HR 0.69) - Also reported: borderline increased kidney cancer signal (HR 1.38, 95% CI 0.99–1.93) requiring longer follow-up
2026 Systematic Review and Meta-Analysis — Frontiers in Oncology - Pooled data from multiple observational studies (261,962 participants) - Ovarian cancer: pooled HR 0.57 (95% CI 0.46–0.71, p < 0.00001) - Prediction interval (95% PI 0.46–0.71) remained below 1.0 - No significant association with breast, thyroid, kidney, or prostate cancers
2. Ovarian Cancer Survival — GLP-1 RA Use After Diagnosis
Wang et al., Population-Based Cohort (Global Federated Health Database), 2024–25 - Matched cohort: 1,023 GLP-1 RA users vs. 1,023 non-users, all with ovarian cancer - All-cause mortality: 7.94% (users) vs. 19.71% (non-users) - HR for death: 0.45 (95% CI 0.35–0.59, log-rank p < 0.001) — 55% lower mortality - Consistent benefit across most subgroups (chemotherapy, PARP inhibitor recipients) - No significant benefit in patients with heart failure or chronic kidney disease (subgroup)
3. Mendelian Randomization — Causal Inference for GLP-1R Activity
*Nature Communications Medicine, 2026 - Used genetic instruments predicting pancreatic GLP-1 receptor expression as a proxy for pharmacologic GLP-1R activation - Overall ovarian cancer: OR 0.94 (95% CI 0.89–1.00) per SD increase in GLP-1R expression - Endometrioid ovarian cancer (ENOC): OR 0.83 (95% CI 0.72–0.95)* - Splice-event validation: OR 0.13 (95% CI 0.02–0.86) for ENOC - Mediation analysis: effect partially mediated by lower body weight and improved lipid metabolism - No significant association with high-grade serous or other histotypes
---
Mechanistic Rationale
GLP-1 RAs may reduce ovarian cancer risk through several interrelated pathways: 1. Weight reduction — obesity is an established risk factor for endometrioid ovarian cancer 2. Improved insulin sensitivity — hyperinsulinemia promotes IGF-1 signaling, a known mitogen in epithelial ovarian cancer 3. Anti-inflammatory effects — reduction in chronic low-grade inflammation associated with adiposity 4. Lipid metabolism modulation — improved lipoprotein profiles may reduce cancer-permissive microenvironments 5. Direct GLP-1R signaling in ovarian tissue — preclinical data suggest antiproliferative effects, though human data are limited
The MR study's mediation analysis provides the strongest evidence that metabolic improvements (weight, lipids) are key mediators, with possible direct receptor-mediated effects.
---
Limitations
| Limitation | Impact | |---|---| | Observational design (all cohorts) | Residual confounding by indication, health-seeking behavior, concomitant medications (metformin, statins) | | Short follow-up relative to cancer latency | Long-term effects may differ from current estimates | | Histotype heterogeneity | Strongest MR signal for ENOC; limited data on other subtypes | | No ovarian-cancer-specific randomized trials | Highest level of evidence still lacking | | Confounding by weight loss | Cannot fully separate drug effect from weight-loss effect | | Differential drug class effects | Tirzepatide (dual GIP/GLP-1 agonist) showed increased gynecologic tumor signal at 15 mg/week in one analysis — not all incretin therapies are equivalent |
---
Clinical Implications
For Risk Counseling - GLP-1 RAs can be described as not increasing ovarian cancer risk and likely reducing risk, particularly in women with obesity or metabolic syndrome - The protective effect appears strongest for endometrioid ovarian cancer, which is obesity-linked - GLP-1 RAs should not replace established risk-reduction strategies (genetic counseling, risk-reducing salpingo-oophorectomy, surveillance) in high-risk patients
For Patients with Existing Ovarian Cancer - Emerging data suggest a survival benefit, but this is hypothesis-generating rather than practice-changing - GLP-1 RA use for metabolic indications (diabetes, weight management) is reasonable in ovarian cancer survivors - Formal prospective trials of GLP-1 RAs as adjunctive therapy in ovarian cancer are warranted
For Research Priorities - Prospective trials with ovarian cancer incidence as a prespecified endpoint in high-risk populations - Histotype-stratified analyses in future registries and cohorts - Mechanistic studies of GLP-1 signaling in the ovarian tumor microenvironment - Longer-term safety data, particularly for dual/triple incretin agonists
---
Bottom Line (For Clinical Use)
Current evidence strength: Moderate for risk reduction; moderate for survival benefit (observational); limited for causal inference (MR supports causality for ENOC specifically). Clinical recommendation: GLP-1 RAs are safe and potentially beneficial from an ovarian cancer perspective when prescribed for their approved metabolic indications. They are not currently indicated as cancer-preventive or cancer-therapeutic agents. NEXT: Await results from ongoing/planned prospective trials before incorporating GLP-1 RAs into formal cancer risk-reduction protocols.